Carboplatin 150mg Injection

Carboplatin 150mg Injection is a second-generation platinum-based antineoplastic agent specifically developed to provide the potent anti-tumor activity of cisplatin but with a significantly improved safety profile. As a cytotoxic alkylating agent, Carboplatin 150mg Injection functions by forming reactive platinum complexes that bind to nucleophilic groups on DNA. These complexes create both inter-strand and intra-strand cross-links within the DNA helix, effectively “handcuffing” the genetic material. This physical obstruction prevents DNA replication and transcription, triggering cell cycle arrest and inducing apoptosis (programmed cell death) in rapidly dividing cancer cells. Because the molecule features a cyclobutane dicarboxylate ligand, it is more stable in the bloodstream than its predecessor, leading to reduced severity of side effects such as nausea, kidney damage (nephrotoxicity), and nerve damage (neurotoxicity). Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for treating ovarian and lung cancers, offering a powerful balance between high efficacy and patient tolerability.

Indications / Uses of Carboplatin 150mg Injection

Carboplatin 150mg Injection is commonly prescribed for the specialized management of the following malignancies:

• Advanced Ovarian Cancer: It is the gold standard for the initial treatment of advanced ovarian carcinoma, typically administered in combination with other chemotherapeutic agents like paclitaxel. It is also indicated for the palliative treatment of patients with recurrent ovarian cancer.
• Small Cell Lung Cancer (SCLC): The medication is a key component of combination regimens used to treat this aggressive form of lung cancer, helping to shrink tumors and extend survival.
• Non-Small Cell Lung Cancer (NSCLC): Carboplatin 150mg Injection is frequently used as a first-line therapy for patients with advanced NSCLC, particularly those who have comorbidities that make them ineligible for cisplatin.
• Head and Neck Cancer: In certain clinical protocols, it serves as an effective alternative to cisplatin for the treatment of squamous cell carcinomas of the head and neck.

Key Features

• Reduced Non-Hematologic Toxicity: The primary feature of Carboplatin 150mg Injection is its lower incidence of severe nausea, vomiting, and kidney damage compared to cisplatin, allowing for better patient quality of life.
• Precision Dosing (Calvert Formula): Unlike most chemotherapies based on body surface area, Carboplatin dosing is often calculated using the Calvert formula, which targets a specific Area Under the Curve (AUC) based on the patient’s kidney function (GFR), ensuring personalized therapeutic exposure.
• 150mg Vial Versatility: The 150mg strength is an intermediate vial size that facilitates efficient compounding of these individualized doses, minimizing drug waste in the pharmacy.
• Cross-Linking Mechanism: Its ability to form stable DNA adducts ensures a durable cytotoxic effect against tumor cells.
• Synergistic Compatibility: It pairs exceptionally well with taxanes (like paclitaxel) and gemcitabine, forming the backbone of many standard oncology protocols.

Storage for Carboplatin 150mg Injection

To preserve the chemical stability and ultimate potency of the platinum complex, Carboplatin 150mg Injection should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the vial in its original outer carton to protect the solution from light, as light exposure can degrade the active compound over time. Do not freeze the medication. Once diluted for infusion, the solution is chemically stable for a specific period (often up to 8 hours at room temperature or 24 hours under refrigeration), but immediate use is recommended to ensure microbiological safety. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Important Note on Carboplatin 150mg Injection

The administration of Carboplatin 150mg Injection comes with a specific equipment warning: Do not use needles or intravenous sets containing aluminum parts. Aluminum reacts with Carboplatin to form a black precipitate, rendering the drug ineffective and potentially dangerous. Only stainless steel needles should be used.

While it is less toxic to the kidneys than cisplatin, myelosuppression (bone marrow suppression) is the dose-limiting toxicity of Carboplatin. It causes Thrombocytopenia (low platelet count) more frequently and severely than cisplatin, increasing the risk of bruising and bleeding. Leukopenia and anemia are also common. Complete blood counts (CBC) must be monitored frequently, and nadirs (lowest points) usually occur around day 21.

Hypersensitivity reactions are a known risk, particularly in patients who have received multiple courses of platinum therapy (often appearing after the 6th or 7th dose). Symptoms can include rash, hives, erythema, and hypotension. Dosing must be carefully calculated using renal function tests (Creatinine Clearance) to avoid overdose. By strictly following these professional guidelines and avoiding aluminum equipment, healthcare providers can safely maximize the therapeutic potential of Carboplatin 150mg Injection.